Premium
Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid‐Derived Suppressor Cells and Heightening Immunogenicity
Author(s) -
Zhang Tian,
Xiong Honggang,
Ma Xianbin,
Gao Yuan,
Xue Peng,
Kang Yuejun,
Sun ZhiJun,
Xu Zhigang
Publication year - 2021
Publication title -
small methods
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.66
H-Index - 46
ISSN - 2366-9608
DOI - 10.1002/smtd.202100115
Subject(s) - tumor microenvironment , cancer research , immunotherapy , immune system , immunogenicity , myeloid derived suppressor cell , cancer immunotherapy , medicine , foxp3 , t cell , immune checkpoint , adjuvant , galectin 1 , immunology , cancer , suppressor
Abstract Tumor‐induced immune suppression mediated by myeloid‐derived suppressor cells (MDSCs) and insufficient immunogenicity are two major factors for the poor overall response rate to the immune checkpoint blockade (ICB). Here, a tumor microenvironment responsive nanoprodrug (FIT nanoparticles) is presented for co‐delivering tadalafil (TAD) and indocyanine green (ICG) photosensitizer to simultaneously targeting intratumor MDSCs and amplifying tumor immunogenicity. The resulting nanoprodrug shows high drug loading (nearly 100%), tumor‐specific release, and robust therapeutic efficacy by virtue of promoting immunogenic cell death (ICD) induction and alleviation of MDSCs for augmenting the photothermal immunotherapy. In an in vivo colon tumor model, the released TAD in the tumor can effectively ameliorate MDSCs immunosuppressive activity, while the photosensitizer ICG is capable of inducing ICD to promote sufficient dendritic cells maturation and T cell infiltration. The results reported here may provide a superior candidate of adjuvants for strengthening immune response and ICB efficacy.